Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells

Gravina,Giovanni  Luca; Ranieri,Guido; Muzi,Paola; Marampon,Francesco; Mancini,Andrea; Di Pasquale,Boris; Di Clemente,Luigi; Dolo,Vincenza; D'Alessandro,Anna  Maria; Festuccia,Claudio

doi:10.3892/or.2012.2192

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells

Authors:
- Giovanni Luca Gravina
- Guido Ranieri
- Paola Muzi
- Francesco Marampon
- Andrea Mancini
- Boris Di Pasquale
- Luigi Di Clemente
- Vincenza Dolo
- Anna Maria D'Alessandro
- Claudio Festuccia
View Affiliations

Affiliations: Department of Biotechnological and Applied Clinical Science, Laboratory of Radiobiology, University of L'Aquila, L’Aquila, Italy, Division of Urology, San Salvatore Hospital, L’Aquila, Italy, Department of Biotechnological and Applied Clinical Science, General Pathology Laboratory, University of L'Aquila, L'Aquila, Italy, Department of Biotechnological and Applied Clinical Science, Biochemistry Laboratory, University of L'Aquila, L'Aquila, Italy, Division of Urology, San Salvatore Hospital, L’Aquila, Italy, Department of Health, Life and Enviromental Sciences, Clinical pathology laboratory, University of L'Aquila, L'Aquila, Italy
Published online on: December 18, 2012 https://doi.org/10.3892/or.2012.2192
Pages: 1189-1195

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA methylation might be the earliest somatic genome changes in prostate cancer that also play an important role in the process of tumor invasion, growth and metastasis. In recent years, several inhibitors of DNA methyltransferases (DNMTis) have been developed and evaluated in pre-clinical models and in clinical trials. While these compounds are effective in the treatment of hematological conditions, clinical trials in solid tumors and in prostate cancer have shown limited or no efficacy. This may be attributed to inappropriate dose regimens leading to toxicity-related adverse events. As with other anti-target compounds, one of the obstacles encountered with DNMTis in prostate cancer could be the inability to select patients for the clinical studies as well as the inability to monitor the efficacy of the drug if not the conclusion of the study. Primary cultures derived from human prostatic tissues harvested from patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) as well as neoplastic and non-neoplastic prostate cell lines were tested for DNMT expression/activity and to monitor azacitidine molecular efficacy. We observed that in primary cultures the levels of DNMT activity as well as the protein levels of DNMT1, DNMT3a and DNMT3b were higher in cultures derived from PCa compared to BPH tissue samples and significantly higher in cultures derived from PCa with Gleason scores ≥7 compared to those observed in cultures derived from Gleason scores <7. In addition, DNMT activity as well as DNMT1, DNMT3a and DNMT3b levels were higher in PCa cell lines compared to their non-neoplastic counterparts. Although DNMT activity was higher in high tumorigenic/aggressive PCa cell lines compared to low tumorigenic/aggressive cell lines, only the levels of DNMT3a and DNMT3b were significantly higher in the first group of cells, suggesting that DNMT1 activity is related to the transition to non-neoplastic versus neoplastic phenotype whereas the de novo methylation enzymes were mainly related to progression. Nevertheless, the comparison in the more aggressive PC3 cell derivatives (PC3-LN4 cells) also possessed higher levels of DNMT1 compared to PC3 and PC3M from which these cells were derived. Collectively, our results confirm previous data on the increased methylation in more aggressive tumors supporting the use of DNMTis in advanced prostate cancer. In addition, since glutathione S-transferase-π (GSTP1) was re-expressed or its protein levels were increased after treatment with non-toxic azacitidine doses and since GSTP1 can easily be measured in patient sera, the monitoring of this protein may aide in the evaluation of therapy in future clinical trials.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin. 56:106–130. 2006.
2	Kirby R: Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nat Clin Pract Urol. 2:298–303. 2005. View Article : Google Scholar : PubMed/NCBI
3	Bedford M and van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 47:5274–5276. 1987.PubMed/NCBI
4	Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG and De Marzo AM: Hypermethylation of the human glutathione S-transferase-π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol. 163:923–933. 2003.
5	Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB and Nelson WG: CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 7:531–536. 1998.PubMed/NCBI
6	Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD, Nelson WG and Kensler TW: Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 61:103–109. 2001.
7	Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, et al: GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 159:1815–1826. 2001. View Article : Google Scholar : PubMed/NCBI
8	Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ and Wolf CR: Increased skin tumorigenesis in mice lacking π-class glutathione S-transferases. Proc Natl Acad Sci USA. 95:5275–5280. 1998.
9	De Marzo AM, Marchi VL, Epstein JI and Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 155:1985–1992. 1999.PubMed/NCBI
10	Kano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 99:247–257. 1999. View Article : Google Scholar : PubMed/NCBI
11	Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, et al: Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem. 282:12249–12259. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bai T, Tanaka T, Yukawa K and Umesaki N: A novel mechanism for acquired cisplatin-resistance: Suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2′-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells. Int J Oncol. 28:497–508. 2006.PubMed/NCBI
13	Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM and Tombolini V: Biological Rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 9:305–321. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, et al: 5-aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res. 13:2136–2143. 2007.
15	Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA and Karpf AR: Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res. 6:1365–1374. 2008.
16	Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, et al: Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 15:3881–3888. 2009. View Article : Google Scholar : PubMed/NCBI
17	Iwata H, Sato H, Suzuki R, Yamada R, Ichinomiya S, Yanagihara M, et al: A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol. 38:1653–1661. 2011.PubMed/NCBI
18	Perry AS, Foley R, Woodson K and Lawler M: The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer. 13:357–377. 2006. View Article : Google Scholar : PubMed/NCBI
19	Pulukuri SM and Rao JS: Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol. 26:863–871. 2005.
20	Festuccia C, Gravina GL, D’Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, et al: Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol. 33:381–388. 2008.
21	Festuccia C, Gravina GL, D’Alessandro AM, Muzi P, Millimaggi D, Dolo V, et al: Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer. 16:401–413. 2009. View Article : Google Scholar : PubMed/NCBI
22	van Groeningen CJ, Leyva A, O’Brien AM, Gall HE and Pinedo HM: Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 46:4831–4836. 1986.
23	Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, et al: A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 84:87–89. 1998.
24	Kastl L, Brown I and Schofield AC: Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells. Int J Oncol. 36:1235–1241. 2010.PubMed/NCBI
25	Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, Jannini EA and Festuccia C: Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology. 152:4550–4561. 2011. View Article : Google Scholar : PubMed/NCBI
26	Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C and Bologna M: Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate. 68:793–801. 2008. View Article : Google Scholar
27	Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V and Festuccia C: 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate. 70:1166–1178. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sinisi AA, Chieffi P, Pasquali D, Kisslinger A, Staibano S, Bellastella A and Tramontano D: EPN: a novel epithelial cell line derived from human prostate tissue. In Vitro Cell Dev Biol Anim. 23:165–172. 2002. View Article : Google Scholar : PubMed/NCBI
29	Tepper CG, Boucher DL, Ryan PE, et al: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 62:6606–6612. 2002.PubMed/NCBI
30	Craft N, Shostak Y, Carey M, et al: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5:280–288. 1999. View Article : Google Scholar : PubMed/NCBI
31	Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL and Pienta KJ: VCaP, a cell-based model system of human prostate cancer. In Vivo. 15:163–168. 2001.PubMed/NCBI
32	Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD and Keller ET: Bone metastatic LNCaP-derivative C4–2B prostate cancer cell line mineralizes in vitro. Prostate. 47:212–218. 2001.
33	Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ and Fidler IJ: Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 2:1627–1636. 1996.PubMed/NCBI
34	Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L and Bologna M: Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res. 7:131–138. 1995.PubMed/NCBI
35	Festuccia C, Angelucci A, Gravina GL, Muzi P, Miano R, Vicentini C and Bologna M: Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. Int J Oncol. 26:1353–1362. 2005.PubMed/NCBI
36	Gravina GL, Biordi L, Martella F, Flati V, Ricevuto E, Ficorella C, Tombolini V and Festuccia C: Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol. 35:1133–1139. 2009.PubMed/NCBI
37	Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, et al: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 11:3604–3608. 2005. View Article : Google Scholar : PubMed/NCBI
38	Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 106:1794–1803. 2006. View Article : Google Scholar : PubMed/NCBI
39	Chiam K, Centenera MM, Butler LM, Tilley WD and Bianco-Miotto T: GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells. PLoS One. 6:e256342011.PubMed/NCBI
40	Mulder TP, Peters WH, Wobbes T, Witteman BJ and Jansen JB: Measurement of glutathione S-transferase P1-1 in plasma: pitfalls and significance of screening and follow-up of patients with gastrointestinal carcinoma. Cancer. 80:873–880. 1997. View Article : Google Scholar : PubMed/NCBI
41	Oude Ophuis MB, Mulder TP, Peters WH and Manni JJ: Plasma glutathione S-transferase P1-1 levels in patients with head and neck squamous cell carcinoma. Cancer. 82:2434–2438. 1998.
42	Prior C, Guillen-Grima F, Robles JE, Rosell D, Fernandez-Montero JM, Agirre X, et al: Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol. 28:681–686. 2010. View Article : Google Scholar : PubMed/NCBI
43	Patra SK, Patra A, Zhao H and Dahiya R: DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 33:163–171. 2002. View Article : Google Scholar : PubMed/NCBI